Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
Rami S. Komrokji, Avani Singh, Najla Al Ali, Onyee Chan, Eric Padron, Kendra Sweet, Andrew Kuykendall, Jeffrey E. Lancet, David A. Sallman
Topics & Concepts
VenetoclaxMyelodysplastic syndromesMedicineHypomethylating agentOncologyAzacitidineInternal medicineLeukemiaBioinformaticsGeneticsBiologyBone marrowGeneDNA methylationGene expressionChronic lymphocytic leukemiaAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia Treatments